BSX - Boston Scientific Corporation
A medical device innovator specializing in minimally invasive interventions across cardiology, urology, and endoscopy.
Finlify Score
28.8 / 100
Data Quality
PARTIAL
Penalty
-1.0
Sector
Health Care
Close Price
$46.00
-0.09%
52W Range
$42.20 - $109.50
Market Cap
$63.4B
-0.1%Compared to previous day
2026 Q1 Revenue
$5.2B
-1.6%Changes from last reporting quarter
2026 Q1 EPS
$0.00
Diluted shares
Analyst Rating
39 analysts in latest ratings feed
RSI
56.9
40-70 moderate
2Y Range Position
6%
-58.0% from high / +9.0% from low
Beta
0.57
Relative to market benchmark
MACD
0.53
MACD line -0.31 / signal line -0.84
Fundamental Trend
Growth 30.4Financial Health
Quality 78.5Data Quality
PARTIALValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID28.8 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $5.2B-1.6% | $5.3B+4.4% | $5.1B+0.1% | $5.1B+8.5% |
| Gross Profit | $3.6B-1.8% | $3.7B+3.9% | $3.5B+3.5% | $3.4B+6.6% |
| Operating Income | $1.1B+33.5% | $825M-21.3% | $1.0B+28.0% | $819M-11.1% |
| Net Income | $1.3B+99.9% | $670M-11.3% | $755M-5.0% | $795M+18.3% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jul 25, 2026
Finlify's quantitative signal for Boston Scientific Corp (BSX) on 2026-07-23 is 'AVOID', with a Finlify Score of 28.1 out of 100. This low score appears to be influenced by weak technical momentum and a low fundamental trend, alongside a deduction for 'PARTIAL' data quality.
Technical
The asset exhibits very low Relative Strength at 2.4/100 and a low Accumulation / Volume score of 14.9/100, which suggests a lack of buying pressure. BSX has experienced a significant 60-day return of -27.3% and is currently -58.5% from its 52-week high, indicating considerable recent downward price action.
Fundamentals
While Financial Quality appears relatively strong at 78.5/100, the Fundamental Trend score is low at 30.4/100. The asset trades at a P/E of 22.9x, a P/B of 5.8x, and a P/S of 3.3x, and currently does not offer a dividend yield. The use of an EPS proxy for the latest financial period ending 2026-03-31 is noted under data quality flags.
Macro Context
The macro environment, with CPI YoY at 3.7% and a 10Y Treasury Yield at 4.7%, suggests a backdrop of elevated inflation and higher interest rates. This environment may present challenges for growth-oriented companies like BSX, potentially influencing future valuation and cost of capital.
Key Risks
- Significant recent price decline and weak technical momentum, as indicated by a 60-day return of -27.3% and a Relative Strength score of 2.4/100.
- The upcoming earnings report on 2026-07-29 could introduce additional volatility and impact the asset's performance.
- The 'PARTIAL' data quality, including the use of an EPS proxy, suggests that data coverage may limit the full confidence in the quantitative signal.